Format

Send to

Choose Destination
J Gen Intern Med. 2019 Jul 16. doi: 10.1007/s11606-019-05149-6. [Epub ahead of print]

Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies.

Author information

1
Collaboration for Research Integrity and Transparency, Yale Law School, New Haven, CT, 06510, USA.
2
Center for Outcomes Research and Evaluation (CORE), Yale New Haven Hospital, New Haven, CT, 06510, USA.
3
Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT, 06510, USA.
4
Department of Medicine, University of California, San Francisco School of Medicine, San Francisco, CA, 94115, USA.
5
Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, 06510, USA.
6
Collaboration for Research Integrity and Transparency, Yale Law School, New Haven, CT, 06510, USA. joseph.ross@yale.edu.
7
Center for Outcomes Research and Evaluation (CORE), Yale New Haven Hospital, New Haven, CT, 06510, USA. joseph.ross@yale.edu.
8
Section of General Medicine, Department of Internal Medicine, Yale School of Medicine, P.O. Box 208093, New Haven, CT, 06520, USA. joseph.ross@yale.edu.
9
Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, 06510, USA. joseph.ross@yale.edu.
10
National Clinician Scholars Program, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, 06510, USA. joseph.ross@yale.edu.
PMID:
31313117
DOI:
10.1007/s11606-019-05149-6

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center